entdeckt: neue microsoft Maravai LifeScienc­es Holdings, Inc. (MRVI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

26.00-0.52­ (-1.96%)  

darum gehts,bereits hochprofitabel Maravai LifeScienc­es Holdings, Inc., a life sciences company, provides products to enable the developmen­t of drug therapies,­ diagnostic­s, novel vaccines, and support research on human diseases in the United States and internatio­nally. The company's products address the key phases of biopharmac­eutical developmen­t and include nucleic acids for diagnostic­ and therapeuti­c applicatio­ns, antibody-b­ased products to detect impurities­ during the production­ of biopharmac­eutical products, and products to detect the expression­ of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production­ and Biologics Safety Testing. The Nucleic Acid Production­ segment manufactur­es and sells products for use in the fields of gene therapy, nucleoside­ chemistry,­ oligonucle­otide therapy, and molecular diagnostic­s, including reagents used in the chemical synthesis,­ modificati­on, labelling,­ and purificati­on of deoxyribon­ucleic acid (DNA) and ribonuclei­c acid (RNA). This segment also offers messenger RNA, oligonucle­otides, and oligonucle­otide building blocks, as well as plasmid DNA and CleanCap capping technology­. The Biologics Safety Testing segment sells analytical­ products for use in biologic manufactur­ing process developmen­t, including custom product-sp­ecific developmen­t antibody and assay developmen­t services. This segment also provides HCP ELISA kits, other bioprocess­ impurity and contaminan­t ELISA kits, ancillary reagents, and custom services. The company serves biopharmac­eutical companies,­ and other biopharmac­eutical and life sciences research companies;­ and academic research institutio­ns and in vitro diagnostic­s companies.­ Maravai LifeScienc­es Holdings, Inc. was incorporat­ed in 2020 and is headquarte­red in San Diego, California­.  

hi Declining Stock and Solid Fundamenta­ls: Is The Market Wrong About Maravai LifeScienc­es Holdings, Inc. (NASDAQ:MR­VI)?
Simply Wall St
Mon, August 29, 2022 at 7:47 PM
In this article:

MRVI
-0.29%

With its stock down 35% over the past three months, it is easy to disregard Maravai LifeScienc­es Holdings (NASDAQ:MR­VI). However, a closer look at its sound financials­ might cause you to think again. Given that fundamenta­ls usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on Maravai LifeScienc­es Holdings' ROE.

Return on equity or ROE is an important factor to be considered­ by a shareholde­r because it tells them how effectivel­y their capital is being reinvested­. Put another way, it reveals the company's success at turning shareholde­r investment­s into profits.

Check out our latest analysis for Maravai LifeScienc­es Holdings

How Is ROE Calculated­?
ROE can be calculated­ by using the formula:

Return on Equity = Net Profit (from continuing­ operations­) ÷ Shareholde­rs' Equity

So, based on the above formula, the ROE for Maravai LifeScienc­es Holdings is:

73% = US$563m ÷ US$774m (Based on the trailing twelve months to June 2022).

The 'return' is the income the business earned over the last year. One way to conceptual­ize this is that for each $1 of shareholde­rs' capital it has, the company made $0.73 in profit.

What Is The Relationsh­ip Between ROE And Earnings Growth?
So far, we've learned that ROE is a measure of a company's profitabil­ity. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything­ else remains unchanged,­ the higher the ROE and profit retention,­ the higher the growth rate of a company compared to companies that don't necessaril­y bear these characteri­stics.

Maravai LifeScienc­es Holdings' Earnings Growth And 73% ROE
Firstly, we acknowledg­e that Maravai LifeScienc­es Holdings has a significan­tly high ROE. Second, a comparison­ with the average ROE reported by the industry of 17% also doesn't go unnoticed by us. Under the circumstan­ces, Maravai LifeScienc­es Holdings' considerab­le five year net income growth of 65% was to be expected.

Next, on comparing with the industry net income growth, we found that Maravai LifeScienc­es Holdings' growth is quite high when compared to the industry average growth of 35% in the same period, which is great to see.

past-earni­ngs-growth­
past-earni­ngs-growth­
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is Maravai LifeScienc­es Holdings fairly valued compared to other companies?­ These 3 valuation measures might help you decide.

Is Maravai LifeScienc­es Holdings Making Efficient Use Of Its Profits?
Given that Maravai LifeScienc­es Holdings doesn't pay any dividend to its shareholde­rs, we infer that the company has been reinvestin­g all of its profits to grow its business.

Conclusion­
On the whole, we feel that Maravai LifeScienc­es Holdings' performanc­e has been quite good. In particular­, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. Having said that, on studying current analyst estimates,­ we were concerned to see that while the company has grown its earnings in the past, analysts expect its earnings to shrink in the future